Inmagene receives FDA clearance for Phase I trial of immunological disease BTK inhibitor asset
A small molecule BTK inhibitor, IMG-004 is being developed to potentially treat immunological diseases.

A small molecule BTK inhibitor, IMG-004 is being developed to potentially treat immunological diseases.
Intrommune CEO Michael Nelson details plans for a Phase II trial in children with peanut allergies slated for late 2022…
ByDupixent (dupilumab) is expected to maintain its market advantage for moderate-to-severe atopic dermatitis despite competition.
ByThe trial will have 200 adult and adolescent subjects with Grade III-IV aGVHD, or Grade II aGVHD with reduced GI…
The discovery of the VB variant of human immunodeficiency virus (HIV) underscores the need to mitigate the global HIV epidemic.
ByMerck will use Twintelligent RCTs to integrate prognostic information from Digital Twins into its randomised controlled trials.
Clinical Trials Arena lists the top five terms tweeted on immunology in Q4 2021, based on data from GlobalData’s Pharmaceuticals…
One of the trials will enrol moderate-to-severe active rheumatoid arthritis patients.